Indaptus Therapeutics Inc INDP
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $2.53
- Day Range
- $2.43–2.53
- 52-Week Range
- $0.92–12.03
- Bid/Ask
- $2.46 / $2.57
- Shares Outstanding
- 133.24M
- Market Cap
- $327.78M
- Volume/Avg
- 33,470 / 997,062
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Indaptus Therapeutics Inc is a clinical biotechnology company that has developed a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. Its approach is based on the hypothesis that efficient activation of both innate and adaptive immune cells and associated anti-tumor and anti-viral immune responses will require a multi-targeted package of immune system activating signals that can be administered safely intravenously. Its patented technology is composed of single strains of attenuated and killed, non-pathogenic, Gram-negative bacteria, designed to have reduced i.v. toxicity, but largely uncompromised ability to prime or activate many of the cellular components of innate and adaptive immunity. Its candidate, Decoy20 is for patients with solid tumors.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 5
- Website
- https://www.indaptusrx.com
Valuation
|
Metric
|
INDP
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 229.60 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
INDP
|
|---|---|
Quick Ratio | 1.61 |
Current Ratio | 2.34 |
Interest Coverage | — |
Quick Ratio
INDP
Profitability
|
Metric
|
INDP
|
|---|---|
Return on Assets (Normalized) | −286.33% |
Return on Equity (Normalized) | −865.14% |
Return on Invested Capital (Normalized) | −523.20% |
Return on Assets
INDP
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|ZTNC#y | LOCK|>y?P | $123B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|GZLt@?R | LOCK|dK<%F | $71B | |||
| argenx SE ADR
ARGX
| LOCK|mNTS^g! | LOCK|c^? | $54B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|QZ>gsC | LOCK|P$# | $36B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|Zc^Yp< | LOCK|ldy@@ | $36B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|^Pqhg<? | LOCK|K>@$ | $26B | |||
| Moderna Inc
MRNA
| LOCK|J?zcjbg | LOCK|Mt | $25B | |||
| Incyte Corp
INCY
| LOCK|#t$RM?^ | LOCK|#WH | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|D>lXljX | LOCK|c&H | $23B | |||
| BridgeBio Pharma Inc
BBIO
| LOCK|<SQrz% | LOCK|WCM | $16B |
United States